The Role of Interventional Treatment on Hepatocellular Carcinoma Combined with Portal Vein Tumor Thrombosis
Yao Wenwo
Abstract
Yao Wenwo
Abstract
Objective:To study the indication and method of interventional treatment on hepatocellular carcinoma combined with portal trunk and/or first level branch tumor thrombosis.Methods:25 patients with primary liver cancer combined with portal trunk and/or first level branch tumor thrombosis received transcatheter arterial chemoembolization,and partial of them received portal vein stent deployment.Results:A total of 46 procedures were performed in 25 patients,and portal vein stent were deployed in 5 patients.One week after the procedure,11 cases elevated from A to B.1 case elevated from A to C,and 2 cases elevated from B to C according to Child-Pugh classification scheme.One patient developed hepatic encephalopathy 2 days after the procedure.Patency of portal vein stent was maintained until death in4 patients,1 patient was lost follow-up.Surival time ranged from 3 to I5 months(meant 6,4 months),Conclusion:TACE and portal vein stent deployment are safe and effec- tive treatment on primary liver cancer combined with portal trunk and/or first level branch tumor thrombosis,on condition that we have the proper indication and method.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective:To study the indication and method of interventional treatment on hepatocellular carcinoma combined with portal trunk and/or first level branch tumor thrombosis.Methods:25 patients with primary liver cancer combined with portal trunk and/or first level branch tumor thrombosis received transcatheter arterial chemoembolization,and partial of them received portal vein stent deployment.Results:A total of 46 procedures were performed in 25 patients,and portal vein stent were deployed in 5 patients.One week after the procedure,11 cases elevated from A to B.1 case elevated from A to C,and 2 cases elevated from B to C according to Child-Pugh classification scheme.One patient developed hepatic encephalopathy 2 days after the procedure.Patency of portal vein stent was maintained until death in4 patients,1 patient was lost follow-up.Surival time ranged from 3 to I5 months(meant 6,4 months),Conclusion:TACE and portal vein stent deployment are safe and effec- tive treatment on primary liver cancer combined with portal trunk and/or first level branch tumor thrombosis,on condition that we have the proper indication and method.
Key concepts: Medicine, Hepatocellular carcinoma, Portal vein, Thrombosis, Hepatic encephalopathy, Radiology, Portal vein thrombosis, Stent